GNAS Antikörper (N-Term)
Kurzübersicht für GNAS Antikörper (N-Term) (ABIN630216)
Target
Alle GNAS Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- GNAS antibody was raised against the N terminal of GNAS
-
Aufreinigung
- Purified
-
Immunogen
- GNAS antibody was raised using the N terminal of GNAS corresponding to a region with amino acids NPENQFRVDYILSVMNVPDFDFPPEFYEHAKALWEDEGVRACYERSNEYQ
-
-
-
-
Applikationshinweise
-
WB: 1.25 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
GNAS Blocking Peptide, (ABIN5613807), is also available for use as a blocking control in assays to test for specificity of this GNAS antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of GNAS antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- GNAS (GNAS Complex Locus (GNAS))
-
Andere Bezeichnung
- GNAS
-
Hintergrund
- Mutations in GNAS gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, Albright hereditary osteodystrophy, pseudopseudohypoparathyroidism, McCune-Albright syndrome, progressive osseus heteroplasia, polyostotic fibrous dysplasia of bone, and some pituitary tumors.
-
Molekulargewicht
- 46 kDa (MW of target protein)
-
Pathways
- Thyroid Hormone Synthesis, cAMP Metabolic Process, Myometrial Relaxation and Contraction, Embryonic Body Morphogenesis
Target
-